STOCKS TELEGRAPH

Tag: Annovis Bio Stock

  • Annovis Bio (ANVS) Stock Soars After FDA Approval

    Annovis Bio (ANVS) Stock Soars After FDA Approval

    A recent regulatory approval from the U.S. Food and Drug Administration (FDA) has led to a substantial rise in the stock price of Annovis Bio, Inc. (NYSE: ANVS). As of the latest update, ANVS shares have increased by 6.72%, trading at $8.02. This upward trajectory is largely attributed to the announcement of a successful End-of-Phase 2 meeting with the FDA, which took place on October 10, 2024.

    Upcoming Phase 3 Trials

    During the End-of-Phase 2 meeting on October 10, 2024, Annovis secured approval to proceed with pivotal Phase 3 trials for its experimental therapy, buntanetap. With a clear developmental strategy established with the FDA, Annovis is now preparing to submit New Drug Applications (NDAs) that will address both immediate and long-term efficacy.

    Comprehensive Study Design

    The upcoming Phase 3 program will involve two distinct trials. The first will be a 6-month study aimed at confirming the symptomatic effects of buntanetap, while the second, an 18-month trial, is designed to demonstrate potential disease-modifying effects. Annovis intends to conduct both studies; however, a successful completion of the 6-month trial may suffice to support an NDA submission, which could be filed within a year of the study’s initiation.

    Safety Data Assured

    Furthermore, the FDA expressed no concerns regarding the safety data related to buntanetap, including factors such as liver enzymes, drug interactions, dose selection, and pharmacokinetics. The regulatory body also confirmed that development can proceed using the new crystal form of buntanetap.

    Earlier this year, Annovis reported promising results from its Phase 2/3 clinical trial, which involved 353 patients and assessed the treatment’s efficacy in conjunction with standard care medications.

    In anticipation of initiating the highly anticipated Phase 3 trials early next year, Annovis is committed to executing the upcoming clinical trials with the utmost precision. The company will maintain transparent communication with its stakeholders as it progresses towards its goal of delivering this potentially transformative treatment to patients.

  • Buntanetap Study Success Sparks Market Rally In Annovis Bio (ANVS) Stock

    Buntanetap Study Success Sparks Market Rally In Annovis Bio (ANVS) Stock

    The current trading session witnesses a significant surge in the value of Annovis Bio, Inc. (NYSE: ANVS) stocks. At present, Annovis shares display a notable increase of 38.26%, reaching $6.06 on the charts of the US stock exchange. This upturn in ANVS share price follows the release of updated clinical trial data.

    Today, Annovis Bio (ANVS) has disclosed the successful completion of data refinement for its phase II/III investigation of buntanetap in individuals with mild to moderate Alzheimer’s disease (AD). The release of primary efficacy data is anticipated in April.

    Buntanetap (previously recognized as Posiphen or ANVS401) combats neurodegeneration by impeding the generation of various neurotoxic proteins, including amyloid beta, tau, alpha synuclein, and TDP43, thus ameliorating synaptic transmission, axonal transport, and neuroinflammation.

    Dysregulation within these pathways has been identified as the primary cause of neuronal degeneration and eventual demise. By targeting these pathways, buntanetap possesses the potential to reverse neurodegeneration in Alzheimer’s disease.

    Annovis reveals that the company has transitioned from data refinement to the organization and statistical analysis of data for its Alzheimer’s study, which concluded in February. The swift completion of data refinement represents a commendable feat. The ANVS team has exerted considerable effort to furnish reliable data, and anticipation is high for the release of primary results next month.

    The phase II/III AD study was conducted as a randomized, double-blind, placebo-controlled trial aimed at assessing the efficacy, safety, and tolerability of buntanetap in individuals with mild to moderate AD. Over 700 patients were screened, and 353 of them were enrolled and 327 of them completed the study.

    As the company gears up to unveil the primary efficacy data next month, the collective anticipation within the scientific community and financial markets underscores the pivotal role of Annovis Bio in shaping the future landscape of Alzheimer’s research and therapeutic interventions.